Tocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study.

Abstract

Familial dysautonomia (FD) is an autosomal recessive congenital neuropathy, primarily presented in Ashkenazi Jews. The most common mutation in FD patients results from a single base pair substitution of an intronic splice site in the IKBKAP gene which disrupts normal mRNA splicing and leads to tissue-specific reduction of IKBKAP protein (IKAP). To date, treatment of FD patients remains preventative, symptomatic and supportive. Based on previous in vitro evidence that tocotrienols, members of the vitamin E family, upregulate transcription of the IKBKAP gene, we aimed to investigate whether a similar effects was observed in vivo. In the current study, we assessed the effects of tocotrienol treatment on FD patients' symptoms and IKBKAP expression in white blood cells. The initial daily doses of 50 or 100 mg tocotrienol, doubled after 3 months, was administered to 32 FD patients. Twenty-eight FD patients completed the 6-month study. The first 3 months of tocotrienol treatment was associated with a significant increase in IKBKAP expression level in FD patients' blood. Despite doubling the dose after the initial 3 months of treatment, IKBKAP expression level returned to baseline by the end of the 6-month treatment. Clinical improvement was noted in the reported clinical questionnaire (with regard to dizziness, bloching, sweating, number of pneumonia, cough episodes, and walking stability), however, no significant effect was observed in any clinical measurements (weight, height, oxygen saturation, blood pressure, tear production, histamine test, vibration threshold test, nerve conduction, and heart rate variability) following Tocotrienol treatment. In conclusion, tocotrienol treatment appears significantly beneficial by clinical evaluation for some FD patients in a few clinical parameters; however it was not significant by clinical measurements. This open-label study shows the complexity of effect of tocotrienol treatment on FD patients' clinical outcomes and on IKBKAP expression level compared to in vitro results. A longitudinal study with an increased sample size is required in the future to better understand tocotrienol affect on FD patients.

• Authors: David Cheishvili, Channa Maayan, Naama Holzer, Jeanna Tsenter, Elad Lax, Sophie Petropoulos, Aharon Razin
• Journal: Journal of molecular neuroscience : MN (J Mol Neurosci) Vol. 59 Issue 3 Pg. 382-91 (Jul 2016) ISSN: 1559-1166 [Electronic] United States
• PMID: 27129499 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Carrier Proteins
• Elp1 protein, human
• Tocotrienols
• Transcriptional Elongation Factors
• Vitamins

Topics

• Adolescent
• Adult
• Carrier Proteins (blood)
• Child
• Child, Preschool
• Dysautonomia, Familial (drug therapy)
• Female
• Humans
• Infant
• Male
• Pilot Projects
• Tocotrienols (administration & dosage, adverse effects, therapeutic use)
• Transcriptional Elongation Factors
• Vitamins (administration & dosage, adverse effects, therapeutic use)